Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: Results of a 48-month longitudinal cohort study

Clinical Genetics

Volumn 73, Issue 5, 2008, Pages 430-440

  Sims, Katherine B ^a   Pastores, G M ^b   Weinreb, N J ^c   Barranger, J ^d   Rosenbloom, B E ^e   Packman, S ^f   Kaplan, G ^g   Mankin, H ^a   Xavier, R ^a   Angell, J ^h   Fitzpatrick, M A ^h   Rosenthal, D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c University Research Foundation   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e Tower Hematology Oncology Medical Group   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^h GENZYME CORPORATION   (United States)

Author keywords

Bone disease; Gaucher disease; Imiglucerase; Skeletal manifestations

Indexed keywords

IMIGLUCERASE; NARCOTIC ANALGESIC AGENT;

ADOLESCENT; ADULT; AGED; ANXIETY; ARTHRALGIA; ARTICLE; BONE DENSITY; BONE DISEASE; BONE MINERAL; BONE PAIN; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME REPLACEMENT; FEMALE; FEMUR NECK; FLUSHING; GAUCHER DISEASE; HUMAN; LONGITUDINAL STUDY; MALE; MULTICENTER STUDY; MUSCLE HYPERTONIA; OPEN STUDY; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; SCHOOL CHILD; SIDE EFFECT; SPINE; STATISTICAL SIGNIFICANCE; TACHYCARDIA; THORAX PAIN; TREATMENT DURATION; VOMITING;

BONE DENSITY; BONE DISEASES; BONE DISEASES, METABOLIC; COHORT STUDIES; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; SPINE;

EID: 42049119012     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2008.00978.x     Document Type: Article

References (25)

1. Stowens DW, Teitelbaum SL, Kahn AJ et al. Skeletal complications of Gaucher disease. Medicine (Baltimore) 1985: 64 (5): 310-322.
2. Brady RO, Barton NW. Enzyme replacement therapy for Gaucher disease: critical investigations beyond demonstration of clinical efficacy. Biochem Med Metab Biol 1994: 52 (1): 1-9.
3. Grabowski GA, Barton NW, Pastores G et al. Enzyme therapy in type 1 Gaucher disease: Comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995: 122 (1): 33-39.
4. Weinreb NJ, Charrow J, Andersson HC et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: A report from the Gaucher Registry. Am J Med 2002: 113 (2): 112-119.
5. Damiano AM, Pastores GM, Ware JE Jr. The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study. Qual Life Res 1998: 7 (5): 373-386.
6. Giraldo P, Solano V, Perez-Calvo JI et al. Quality of life related to type 1 Gaucher disease: Spanish experience. Qual Life Res 2005: 14 (2): 453-462.
7. Rosenthal DI, Scott JA, Barranger J et al. Evaluation of Gaucher disease using magnetic resonance imaging. J Bone Joint Surg Am 1986: 68 (6): 802-808.
8. Wenstrup RJ, Roca-Espiau M, Weinreb NJ et al. Skeletal aspects of Gaucher disease: A review. Br J Radiol 2002: 75 (Suppl. 1): A2-A12.
9. Pastores GM, Patel MJ, Firooznia H. Bone and joint complications related to Gaucher disease. Curr Rheumatol Rep 2000: 2 (2): 175-180.
10. Wenstrup RJ, Kacena KA, Kaplan P et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res 2007: 22 (1): 119-126.
11. Charrow J, Andersson HC, Kaplan P et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000: 160 (18): 2835-2843.
12. Kanis JA, Johnell O, Oden A et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001: 12 (12): 989-995.
13. Rosenthal DI, Doppelt SH, Mankin HJ et al. Enzyme replacement therapy for Gaucher disease: Skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 1995: 96 (4 Pt 1): 629-637.
14. Wenstrup RJ, Bailey L, Grabowski GA et al. Gaucher disease: Alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood 2004: 104 (5): 1253-1257.
15. Charrow J, Dulisse B, Grabowski G et al. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet 2007: 71 (3): 205-211.
16. Weinreb N, Barranger J, Packman S et al. Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet 2007: 71 (6): 576-588.
17. Pastores GM, Wallenstein S, Desnick RJ et al. Bone density in type 1 Gaucher disease. J Bone Miner Res 1996: 11 (11): 1801-1807.
18. Ciana G, Addobbati R, Tamaro G et al. Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy. J Inherit Metab Dis 2005: 28 (5): 723-732.
19. Schiffmann R, Mankin H, Dambrosia JM et al. Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells Mol Dis 2002: 28 (2): 288-296.
20. Lebel E, Dweck A, Foldes AJ et al. Bone density changes with enzyme therapy for Gaucher disease. J Bone Miner Metab 2004: 22 (6): 597-601.
21. Pastores GM, Weinreb NJ, Aerts H et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004: 41 (4 Suppl. 5): 4-14.
22. Watts NB. Bisphosphonate treatment of osteoporosis. Clin Geriatr Med 2003: 19 (2): 395-414.
23. Kelly C, Bartholomew P, Lapworth A et al. Peripheral bone density in patients with rheumatoid arthritis and factors which influence it. Eur J Intern Med 2002: 13 (7): 423.
24. Robinson RJ, al-Azzawi F, Iqbal SJ et al. Osteoporosis and determinants of bone density in patients with Crohn's disease. Dig Dis Sci 1998: 43 (11): 2500-2506.
25. Marini H, Minutoli L, Polito F et al. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: A randomized trial. Ann Intern Med 2007: 146 (12): 839-847.